The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab.
Aged
Aged, 80 and over
Bevacizumab
/ administration & dosage
Biomarkers
/ analysis
Drug Therapy, Combination
/ adverse effects
Female
Gingival Crevicular Fluid
/ chemistry
Humans
Inflammation
/ diagnosis
Interleukin-17
/ analysis
Male
Middle Aged
Neoplasms
/ blood supply
Neovascularization, Pathologic
/ diagnosis
Osteonecrosis
/ chemically induced
Periodontal Diseases
/ chemically induced
Periodontal Pocket
/ chemically induced
Predictive Value of Tests
Vascular Endothelial Growth Factor A
/ analysis
Zoledronic Acid
/ administration & dosage
Bevacizumab
Crevicular fluid
Interleukin-17
VEGF
Zoledronic acid
mTOR inhibitors
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
29
01
2018
accepted:
31
03
2019
pubmed:
20
4
2019
medline:
26
2
2020
entrez:
20
4
2019
Statut:
ppublish
Résumé
Crevicular fluid was used to assess interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF) in cancer patients receiving zoledronic acid and/or bevacizumab. The markers were also assessed in the serum. Twenty-five patients were included and comprised three groups: patients who received zoledronic acid (n = 9), patients who received bevacizumab (n = 9), and patients who received zoledronic acid combined with bevacizumab (n = 5). One patient received zoledronic acid and everolimus and another received zoledronic acid, bevacizumab, and temsirolimus. IL-17 and VEGF were measured by standard quantitative ELISA kits and assessed in two study points. Twenty-four patients maintained good periodontal health; one had asymptomatic osteonecrosis of the jaw. First assessment: 44 samples were collected; 21 from serum and 23 from crevicular fluid. Second assessment, 6 months later: 11 samples were collected; 6 from serum and 5 from crevicular fluid. IL-17 was detected in all samples, in serum and crevicular fluid, and remained unchanged at both time points. Serum VEGF in patients with bevacizumab alone or combined with zoledronic acid was significantly lower compared with that of patients who received zoledronic acid alone. VEGF was not detected in the crevicular fluid. Crevicular fluid might be an easy, non-invasive means to assess IL-17. The stable values of IL-17 in crevicular fluid and serum and the lack of VEGF in the crevicular fluid could be related to the good periodontal health of our patients. Further studies are needed to assess IL-17 and VEGF in the crevicular fluid in patients with and without periodontal disease.
Identifiants
pubmed: 31001696
doi: 10.1007/s00520-019-04793-2
pii: 10.1007/s00520-019-04793-2
doi:
Substances chimiques
Biomarkers
0
IL17A protein, human
0
Interleukin-17
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
Zoledronic Acid
6XC1PAD3KF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-184Références
Yang B, Hang H, Fung A, Zhao H et al (2014) The role of interleukin 17 in tumour proliferation, angiogenesis and metastasis. Mediat Inflamm 2014:623759. https://doi.org/10.1155/2014/623759
doi: 10.1155/2014/623759
Cheng WC, Hughes FJ, Taams LS (2014) The presence, function and regulation of IL-17 and Th17 cells in periodontitis. J Clin Periodontol 41:541–549. https://doi.org/10.1111/jcpe.12238
doi: 10.1111/jcpe.12238
pubmed: 24735470
Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ, Takayanagi H (2006) Th17 functions as an osteoclastogenic helper T cell subject that links T cell activation and bone destruction. J Exp Med 27(203):2673–2682. https://doi.org/10.1084/jem.20061775
doi: 10.1084/jem.20061775
Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird BA, Lee CS, Shnier R, Portek IJ (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54:1122–1131. https://doi.org/10.1002/art.21749
doi: 10.1002/art.21749
pubmed: 16572447
Gacche RN, Meshram RJ (2013) Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Prog Biophys Mol Biol 113:333–354. https://doi.org/10.1016/j.pbiomolbio.2013.10.001
doi: 10.1016/j.pbiomolbio.2013.10.001
pubmed: 24139944
Bissachi D, Benelli R, Vanzetto C et al (2003) Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives. Cancer Detect Prev 27:229–238
doi: 10.1016/S0361-090X(03)00030-8
Nicolatou-Galitis O, Razis E, Galiti D, Galitis E, Labropoulos S, Tsimpidakis A, Sgouros J, Karampeazis A, Migliorati C (2015) Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving aniresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 120:699–706. https://doi.org/10.1016/j.oooo.2015.08.007
doi: 10.1016/j.oooo.2015.08.007
pubmed: 26455289
Tsao C, Darby I, Ebeling P, Walsh K et al (2013) Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 71:1360–1366. https://doi.org/10.1016/j.joms.2013.02.016
doi: 10.1016/j.joms.2013.02.016
pubmed: 23582590
Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, Denaro V, Santini D, Tonini G (2012) Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J Hematol Oncol 5:56. https://doi.org/10.1186/1756-8722-5-56
doi: 10.1186/1756-8722-5-56
pubmed: 22986334
pmcid: 3472182
Subrahmanyaam MV, Sangyeetha M (2003) Gingival crevicular fluid a marker of the periodontal disease activity. Indian J Clin Biochem 18:5–7. https://doi.org/10.1007/BF02867658
doi: 10.1007/BF02867658
Longo PL, Artese HPC, Horliana ACRT, Gomes GH, Ramito GA et al (2015) Inflammatory markers in gingival crevicular fluid of periodontitis patients with type 2 diabetes mellitus according to glycerine control: a pilot study. Dent Res J (Isfahan) 12:449–455
doi: 10.4103/1735-3327.166193
Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I (2010) A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116:3554–3563. https://doi.org/10.1182/blood-2010-05-283895
doi: 10.1182/blood-2010-05-283895
pubmed: 20664052
pmcid: 4017298
Luo Z, Wang H, Chen J, Kang J, Sun Z, Wu Y (2015) Overexpression and potential regulatory role of IL-17F in pathogenesis of chronic periodontitis. Inflammation 38:978–986. https://doi.org/10.1007/s10753-014-0060-6
doi: 10.1007/s10753-014-0060-6
pubmed: 25384562
Zenobia C, Hajishengallis G (2015) Basic biology and role of interleukin-17 in immunity and inflammation. Periodontol 69:142–159. https://doi.org/10.1111/prd.12083.
doi: 10.1111/prd.12083.
Ajuz N, Antunes H, Mendonca T, Pires F et al (2014) Immunosuppression of interleukin-17 in apical periodontitis lesions. JOE 40:1400–1403. https://doi.org/10.1016/j.joen.2014.03.024
doi: 10.1016/j.joen.2014.03.024
pubmed: 25043329
Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen WJ, Wang S, le AD, Shi S (2010) Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res 25:1668–1679. https://doi.org/10.1002/jbmr.37
doi: 10.1002/jbmr.37
pubmed: 20200952
pmcid: 3154005
Zhang Q, Atsuta I, Liu S, Chen C, Shi S, Shi S, le AD (2013) IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin Cancer Res 19:3176–3188. https://doi.org/10.1158/1078-0432.CCR-13-0042
doi: 10.1158/1078-0432.CCR-13-0042
pubmed: 23616636
pmcid: 5558149
Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G (2016) Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 6:97–104. https://doi.org/10.4103/2231-0762.178742
doi: 10.4103/2231-0762.178742
pubmed: 27114946
pmcid: 4820581
Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA (2011) Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112:195–202. https://doi.org/10.1016/j.tripleo.2011.02.037
doi: 10.1016/j.tripleo.2011.02.037
pubmed: 21622014
Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120. https://doi.org/10.1093/annonc/mdn554
doi: 10.1093/annonc/mdn554
pubmed: 18689864
Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145. https://doi.org/10.1093/annonc/mdn526
doi: 10.1093/annonc/mdn526
pubmed: 18647964
Vladau M, Cimpean AM, Balica RA, Jitariu AA, Popovici RA, Raica M (2016) VEGF/VEGFR2 Axis in periodontal disease progression and angiogenesis: basic approach for a new therapeutic strategy. In Vivo 30:53–60
pubmed: 26709129
Padma R, Anaji S, Indeevar P, Indranil S, Chetan SK (2014) Vascular endothelial growth factor levels in gingival crevicular fluid before and after periodontal therapy. J Clin Diagn Res 8:75–79
Prapulla DV, Sujatha PB, Pradeep AR (2007) Gingival crevicular fluid VEGF levels in periodontal health and disease. J Periodontol 78:1783–1787. https://doi.org/10.1902/jop.2007.070009
doi: 10.1902/jop.2007.070009
pubmed: 17760549
Santini D, Vincenzi B, Battistoni F et al (2007) In vivo perspective study about the effects of weekly low dose administration of zoledronic acid (ZA) on angiogenesis. J Clin Oncol 25(suppl):152
Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G (2003) ZA induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897
pubmed: 12912933
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E (2008) Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 25:346–349. https://doi.org/10.1007/s12032-008-9043-5
doi: 10.1007/s12032-008-9043-5
pubmed: 18204821
Thumbigere-Math V, Michalowicz B, Hughes PJ, Basi DL et al (2016) Serum markers of bone turnover and angiogenesis in bisphosphonate-related osteonecrosis of the jaw patients following discontinuation of long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg 74(4):738–746. https://doi.org/10.1016/j.joms.2015.09.028
doi: 10.1016/j.joms.2015.09.028
pubmed: 26501428